2007 - 2008 Investigation of the targeted therapy for cancer stem cells
2005 - 2006 アポトーシス抑制分子FLIPの新規機能解析
Show all
Papers (97):
Kohei Otomo, Takaki Omura, Yuki Nozawa, Steven J Edwards, Yukihiko Sato, Yuri Saito, Shigehiro Yagishita, Hitoshi Uchida, Yuki Watakabe, Kiyotada Naitou, et al. descSPIM: an affordable and easy-to-build light-sheet microscope optimized for tissue clearing techniques. Nature communications. 2024. 15. 1. 4941-4941
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, et al. A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. npj Precision Oncology. 2024. 8. 1
Shun Morino, Tetsuo Mashima, Fumiyuki Shirai, Satoshi Nagayama, Ryohei Katayama, Hiroyuki Seimiya. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer letters. 2024. 584. 216632-216632
Mingjue Chen, Tetsuo Mashima, Taichi Oishi, Yukiko Muramatsu, Yosuke Seto, Manabu Takamatsu, Naomi Kawata, Shun Morino, Ayane Nakamura, Saori Inaba, et al. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British journal of cancer. 2023
Nobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, Ai Takemoto, Tomoko Oh-Hara, Ken Uchibori, Sophia Subat-Motoshi, Hironori Ninomiya, Kengo Takeuchi, Makoto Nishio, et al. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI insight. 2023
Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, et al. Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12